Hangzhou Alltest Biotech's low ROE and net income growth are...

Hangzhou Alltest Biotech's low ROE and net income growth are worrisome. Despite profit retention, the low ROE indicates that investors may not be reaping benefits. The company's growth lags behind industry average, raising concerns. Future earnings growth and its effect on stock price need assessment.